Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
In animal studies, BPC-157 produced no behavioral changes when given alone at therapeutic doses
IV delivery bypasses the digestive system, providing higher absorption and immediate bloodstream availability compared to oral forms
Originally engineered at Washington State University by the Harding lab and later licensed to M3 Biotechnology, Dihexa retains the angiotensin IV pharmacophore for AT4 receptor binding while incorporating N-hexanoyl and aminohexanoic acid modifications that confer metabolic stability and lipophilic BBB penetration
Bpc-157 is widely discussed in wellness and research communities for its role in recovery-focused protocols under professional guidance
Massage in circular motion for better absorption
US$ 26.86
US$ 22.81
US$ 29.16
